Understanding the costs of drug-related actions is an important aspect of the drug policy. Some of the funds allocated by governments for expenditure to tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, the majority of drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
In Slovenia, there are no budgets attached to the national drug policy documents. Authorities report their total drugrelated expenditure every year, covering both demand and supply reduction activities, but the methodology used is not detailed and data completeness varies every year.
The available data suggest that total drug-related expenditure represented 0.03 % of gross domestic product (GDP) in 2015 and that this proportion varied between 0.02 % and 0.03 % of GDP between 2006 and 2015.
Trend analysis shows that drug-related labelled expenditure increased between 2006 and 2011 in nominal terms. However, after 2008, the pace of growth slowed, which may be a consequence of the public austerity measures that followed the economic recession of 2008. Available data suggest that the total funds available may have been reduced in 2012, following the overall public austerity that was experienced in Slovenia, but remained stable in the following year; however, drug-related funding increased in 2014 and 2015.
In 2015, total drugrelated public expenditure represented 0.03 % of gross domestic product